Last reviewed · How we verify
Arilat — Competitive Intelligence Brief
unknown
Ace-orthologous acetylcholinesterase; Acetylcholinesterase, Acetylcholinesterase
Neuroscience
Live · refreshed every 30 min
Target snapshot
Arilat (carbaryl). Carbaryl works by inhibiting acetylcholinesterase, an enzyme that breaks down the neurotransmitter acetylcholine, leading to overstimulation of nerve cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Arilat TARGET | carbaryl | unknown | Ace-orthologous acetylcholinesterase; Acetylcholinesterase, Acetylcholinesterase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Arilat — Competitive Intelligence Brief. https://druglandscape.com/ci/carbaryl. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing